ProKidney Corp (NASDAQ:PROK) shares traded -1.60% lower at $1.85 on Wall Street last session.
PROK stock price is now 0.45% away from the 50-day moving average and -15.20% away from the 200-day moving average. The market capitalization of the company currently stands at $539.66M.
On September 10, 2024, Guggenheim recently initiated its ‘Buy’ rating on the stock quoting a target price of $6, while ‘Morgan Stanley’ rates the stock as ‘Equal-Weight’
In other news, Weber Darin J., Chief Regulatory Officer sold 16,412 shares of the company’s stock on Sep 19 ’24. The stock was sold for $41,030 at an average price of $2.50. Upon completion of the transaction, the Chief Regulatory Officer now directly owns 103,480 shares in the company, valued at $0.19 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 19 ’24, Officer DARIN J WEBER bought 16,412 shares of the business’s stock. A total of $39,225 was incurred on buying the stock at an average price of $2.39. A total of 39.85% of the company’s stock is owned by insiders.
During the past 12 months, ProKidney Corp has had a low of $1.18 and a high of $4.44. The fifty day moving average price for PROK is $1.8526 and a two-hundred day moving average price translates $2.178425 for the stock.
The latest earnings results from ProKidney Corp (NASDAQ: PROK) was released for 2024-09-30. The company reported revenue of $48.97 million for the quarter, compared to $46.62 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 5.05 percent.
